Premium
Immunogenic properties of a soluble tumor rejection antigen (TSTA) from a simian virus 40‐induced sarcoma
Author(s) -
Rogers Michael J.,
Law Lloyd W.
Publication year - 1979
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910230116
Subject(s) - immunogenicity , antigen , biology , immune system , neoplasm , in vitro , cytotoxicity , virus , microbiology and biotechnology , virology , biochemistry , immunology , genetics
Tumor rejection antigen (TSTA) has been prepared in soluble form and in good yield from the tissue‐culture‐adapted SV40‐induced sarcoma, mKSA, without resorting to the usual extraction procedures of proteolysis, 3 M KCI extraction or treatment with detergents. Chromatography on a Biogel A.5m column of the high‐speed supernatant material yielded a fraction, fraction 5, that contained the most active TSTA (and T antigen). This activity was purified in relation to the tumor‐rejection activity of the cell‐bound TSTA on intact cells or on membranes; a single immunization in the 1 μg to 10 μg protein range strikingly inhibited the growth of the syngeneic neoplasm, mKSA, in tumor‐cell challenges at 5×10″ (500×TD 50 ), The soluble TSTA was immunologically specific and extremely stable. Inhibition of growth was not achieved against Meth A, another BALB/c syngeneic sarcoma, and preparations frozen for 6 months at −20°C maintained their strong specific immunogenicity. The immune deviations of the host that have been reported following inoculations of solubilized (extracted) tumor antigens or crude extracts were not observed in this study using our soluble TSTA. We found no evidence of antigen “overloading;” i.e. an optimal protective effect in a restricted dose range of antigen or with a particular size of tumor‐cell challenge; nor did we observe facilitated tumor growth or inhibition of cell‐mediated immune responses under a variety of conditions.